Lifeward Reports Going Concern Warning Amidst Revenue Decline, Secures Critical Oramed Financing and Strategic Partnerships

summarizeSummary

Lifeward Ltd. issued a going concern warning in its annual report, reporting a 14% revenue decline but narrowed losses. The company secured a critical, highly dilutive strategic financing deal with Oramed Pharmaceuticals and made progress on product development and reimbursement coverage.

check_boxKey Events · Earnings and Guidance · LFWD

• Going Concern Warning Issued

  Management and auditors concluded there is substantial doubt about the company's ability to continue as a going concern due to an accumulated deficit of $284.7 million and anticipated future losses.

• Strategic Oramed Financing Approved

  Shareholders approved a strategic transaction with Oramed Pharmaceuticals, Inc. which includes the acquisition of Oratech Pharma, Inc., the issuance of ordinary shares and pre-funded warrants representing up to 49.99% of fully diluted equity, and up to $20.0 million in senior secured convertible notes ($10.0 million to be issued at closing).

• Revenue Decline and Narrowed Losses

  The company reported a 14% decrease in revenue to $22.0 million for 2025 (from $25.6 million in 2024), primarily due to reduced AlterG sales. However, net loss narrowed to $(19.9) million in 2025 from $(28.9) million in 2024, and net cash used in operating activities improved to $(16.8) million from $(21.7) million.

• Significant Reimbursement Progress

  CMS established a lump-sum Medicare purchase fee of $91,032 for personal exoskeletons (increased to $114,097 in Jan 2026), an Administrative Law Judge ruled in favor of Medicare coverage, and agreements were finalized with BARMER in Germany, Aetna, and Humana Medicare Advantage plans.

auto_awesomeAnalysis · LFWD · Industrial Applications And Services

This annual report reveals Lifeward Ltd. is facing substantial doubt about its ability to continue as a going concern, a critical risk for investors. While the company reported a 14% revenue decline in 2025, it also narrowed its net loss and improved operating cash burn. The approval of the Oramed Pharmaceuticals strategic transaction, involving significant equity issuance (up to 49.99% fully diluted) and $20 million in convertible notes, is a crucial lifeline, albeit highly dilutive. Positive developments in reimbursement coverage from Medicare, BARMER, Aetna, and Humana, along with new product clearances and strategic acquisitions, offer potential for future growth. However, the immediate financial instability and the dilutive nature of the financing are paramount concerns.